article thumbnail

Nelson Advisors invited to Judge the 'HealthInvestor Power List 2024' Awards

Lloyd Price

Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. Nelson Advisors work with Healthcare Technology Founders, Owners and Investors to assess whether they should 'Build, Buy, Partner or Sell' in order to maximise shareholder value.

article thumbnail

'HealthInvestor Power List 2024 Awards - Nelson Advisors Partner Lloyd Price asked to Judge the Awards

Lloyd Price

Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HealthInvestor Awards 2024

Lloyd Price

Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces.

article thumbnail

Association of British HealthTech Industries unveil their Plan for HealthTech manifesto

Lloyd Price

Here are some milestones marking ABHI's involvement in the UK's health tech landscape: 2004: ABHI co-authored a report for the Health Insurance Task Force (HITF). 2007: ABHI co-founded the Ministerial Medical Technology Strategy Group, again aligning with a HITF recommendation. Visit www.nelsonadvisors.co.uk Subscribe Today!

article thumbnail

Ozempic, WeGovy, Trulicity: How GLP-1s influence Pharma and HealthTech shares

Lloyd Price

Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. 2004: First GLP-1 receptor agonist (GLP-1 RA), exenatide, approved for type 2 diabetes treatment.

article thumbnail

Elation Health Announces $50M Series D for Innovative Primary Care

Healthcare IT Today

Elation Health , the clinical-first technology company powering innovation in primary care, today announced a Series D financing round of $50 million. It is an independent, private, owner-managed partnership established in 2004 and headquartered in London, with a U.S. presence in San Francisco.

article thumbnail

Scotland's potential to become a global HealthTech Hub

Lloyd Price

Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions.